Over-the-counter Sudafed doesn’t work. Neither does our system for evaluating older drugs

You would have been forgiven for being surprised on Sept. 12 when a panel of advisers to the Food and Drug Administration concluded that the active ingredient in Sudafed PE and other over-the-counter decongestants is completely ineffective. It was front-page news, birthed myriad explainer stories on the internet, and even inspired a lawsuit against companies that sold the medicine, phenylephrine.

Yet when T.J. Parker, the entrepreneur and pharmacist who sold PillPack to Amazon, saw the news, he tweeted, “Didn’t everyone know this?”

He had a point.

Get unlimited access to award-winning journalism and exclusive events.

Significant increase in earnings – full-year forecast raised – Biotech Investments

Drägerwerk AG & Co. KGaA / Key word(s): Preliminary Results/Change in Forecast Drägerwerk AG & Co. KGaA: Preliminary figures Q3 2023: Significant increase in earnings

October 17, 2023

STAT Virtual Event: ASCO Recap, Live!

Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET. STAT’s reporters, strung-out from several days of ASCO madness, will

June 5, 2024

Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma

SAN DIEGO — The combination of loncastuximab tesirine (Zynlonta) and rituximab achieved promising response rates in patients with relapsed or refractory follicular lymphoma (R/R FL),

December 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.